REG - Intelligent Ultrasnd - Grant of share options

Intelligent UltrasoundAnnouncement

22/12/2020 10:30

RNS Number : 5263J
  
Intelligent Ultrasound Group PLC
  
22 December 2020
  
 

Intelligent Ultrasound Group plc
("the Company")
 
Grant of Share Options
 
 Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial intelligence (AI) software and simulation company, announces the grant of 3,608,264 share options to the Directors and 4,523,245 share options to other management and employees (together the "options") on 21 December 2020 at a price of 15.25 pence per share, representing the closing mid-market price on the date of approval by the Remuneration committee.
Individual Director option grants
 



Director


New grant


Type




Stuart Gall


1,087,498


Non-EMI




Nicholas Sleep


1,033,711


Non-EMI




Ian Whittaker


728,289


Non-EMI




Ian Whittaker


96,500


EMI




Helen Jones


662,266


EMI








3,608,264







 
Following the option grants above, the Directors hold the total number of share options as shown below:
 



Director


Number of options held




Stuart Gall


4,116,498




Nicholas Sleep


3,166,711




Ian Whittaker


2,024,789




Helen Jones


1,662,266








10,970,264




% of share capital on fully diluted basis


3.7%



 
Vesting criteria
The options vest over a period of 36 months from date of grant as shown below and will remain exercisable at any point up until the tenth anniversary of the date of grant.



Number of shares in respect of which the Option shall vest




12/36 vest after 12 months  




1/36 vest per month for 24 months 



Management and employee options
A total of 4,523,245 options have been issued to other management and employees. Each award (regardless of whether it was granted as an EMI award or a non-EMI advantaged award) will ordinarily become exercisable on the third anniversary of grant, subject to the grantee's continued service with the Group and will remain exercisable at any point up until the tenth anniversary of the date of grant.
These option grants are under the Company's EMI scheme where the individual and the grant meets EMI criteria. Grants which do not qualify are under the same rules as the EMI scheme but will not benefit from EMI tax status.
The notification in Appendix 1 to this announcement, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
For further information, please contact:
 



Intelligent Ultrasound Group plc 


www. intelligentultrasound.com




Stuart Gall, CEO 

Helen Jones, CFO


Tel: +44 (0)29 2075 6534 














Cenkos Securities - Nominated Advisor and Broker


Tel:  +44 (0)20 7397 8900 




Giles Balleny / Cameron MacRitchie (Corporate Finance)








Michael Johnson / Julian Morse (Sales) 


















Walbrook PR 


Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com 




Anna Dunphy / Paul McManus 


Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893











 
About Intelligent Ultrasound Group
 
Intelligent Ultrasound (AIM: IUG) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market. Based in Cardiff in the UK and Atlanta in the US, the Group operates two divisions:
 
Clinical AI Division
 
Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in the market include ScanNav Assist, which uses machine-learning based algorithms to automatically identify and grade ultrasound images. GE Healthcare's SonoLyst software on their Voluson SWIFT ultrasound machine incorporates the ScanNav Assist AI technology and has received 510(k) clearance from the FDA for sale in the USA. SonoLyst is the world's first fully integrated AI tool that recognises the 20 views recommended by the International Society of Ultrasound in Obstetrics and Gynaecology mid-trimester practice guidelines for fetal imaging.
 
Products in development include ScanNav Anatomy PNB, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting software for a range of medical procedures. ScanNav Anatomy has been submitted for CE and FDA regulatory approval.
 
Simulation Division 
 
Focusses on hi-fidelity ultrasound education and training through simulation.  Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date almost 1,000 simulators have been sold to over 600 medical institutions around the world.
 
www.intelligentultrasound.com
 
Appendix 1
 
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
 



NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES




1


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Stuart Gall




2


Reason for the notification




a)


Position/status


Chief Executive Officer




b)


Initial notification/amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Full name of the entity


Intelligent Ultrasound Group plc




b)


Legal entity identifier code


213800K4ZVWL4ZYQAZ70




4


Details of the transaction(s)




a)


Description of the financial instrument, type of instrument


Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each




b)


Identification Code


ISIN: GB00BN791Q39




c)


Nature of the transaction


Grant of options over Ordinary Shares




d)


Currency


GBP - British pound




e)


Price(s) and Volume(s)


 
Price - 15,25 pence
Volume - 1,087,498




f)


Aggregated information
-      Price
-      Volume
-      Total


N/A




g)


Date of transaction


21 December 2020




h)


Place of transaction


Off market



 



NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES




1


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Nicholas Sleep




2


Reason for the notification




a)


Position/status


Chief Technical Officer




b)


Initial notification/amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Full name of the entity


Intelligent Ultrasound Group plc




b)


Legal entity identifier code


213800K4ZVWL4ZYQAZ70




4


Details of the transaction(s)




a)


Description of the financial instrument, type of instrument


Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each




b)


Identification Code


ISIN: GB00BN791Q39




c)


Nature of the transaction


Grant of options over Ordinary Shares




d)


Currency


GBP - British pound




e)


Price(s) and Volume(s)


 
Price - 15.25 pence
Volume - 1,033,711




f)


Aggregated information
-      Price
-      Volume
-      Total


N/A




g)


Date of transaction


21 December 2020




h)


Place of transaction


Off market



 



NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES




1


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Ian Whittaker




2


Reason for the notification




a)


Position/status


Chief Operating Officer




b)


Initial notification/amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Full name of the entity


Intelligent Ultrasound Group plc




b)


Legal entity identifier code


213800K4ZVWL4ZYQAZ70




4


Details of the transaction(s)




a)


Description of the financial instrument, type of instrument


Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each




b)


Identification Code


ISIN: GB00BN791Q39




c)


Nature of the transaction


Grant of options over Ordinary Shares




d)


Currency


GBP - British pound




e)


Price(s) and Volume(s)


 
Price - 15.25 pence
Volume - 824,789




f)


Aggregated information
-      Price
-      Volume
-      Total


N/A




g)


Date of transaction


21 December 2020




h)


Place of transaction


Off market



 
 



NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES




1


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Helen Jones




2


Reason for the notification




a)


Position/status


Chief Financial Officer




b)


Initial notification/amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Full name of the entity


Intelligent Ultrasound Group plc




b)


Legal entity identifier code


213800K4ZVWL4ZYQAZ70




4


Details of the transaction(s)




a)


Description of the financial instrument, type of instrument


Options over ordinary shares in Intelligent Ultrasound Group plc with a nominal value of 1 pence each




b)


Identification Code


ISIN: GB00BN791Q39




c)


Nature of the transaction


Grant of options over Ordinary Shares




d)


Currency


GBP - British pound




e)


Price(s) and Volume(s)


 
Price - 15.25 pence
Volume - 662,266




f)


Aggregated information
-      Price
-      Volume
-      Total


N/A




g)


Date of transaction


21 December 2020




h)


Place of transaction


Off market



 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHKKBBBKBDDOBB